SVRA Savara Inc

$SVRA the strongest stocks are getting caught up in the sell off . We will need a day of capitulation hopefully in the next couple of weeks, I would not be a buyer of the stock until I see a confirmation of a capitulation. The fundamentals of the stock/company seem to be intact. It’s reassuring that JP Morgan recently came out with a $12 stock price. Hang in there guys it’s gonna be a rough a few weeks!

$SVRA Near-term, Savara has plenty of catalysts, including the potential approval of Molbreevi in the U.S. on or before its PDUFA date of Nov. 22, 2026, with potential approvals in the U.K. and EU expected in 4Q26 and 1Q27, respectively. Based on our model, which assumes that Molbreevi has blockbuster potential in aPAP across geographies----JPM analysis

$SVRA Piper Sandler maintains an Overweight (or Buy) rating on Savara Inc. (NASDAQ: SVRA) with a price target of $16.00. • Analyst: Yasmeen Rahimi (Piper Sandler) • Rating: Overweight / Buy • Price Target: $16.00 • Key Context: The rating is supported by ongoing optimism surrounding Savara's inhaled therapy Molbreevi (molgramostim) for autoimmune pulmonary alveolar proteinosis (aPAP), following FDA acceptance of its resubmitted Biologics License Application (BLA) with a target action date of November 22, 2026.

quiet one nobody is pricing yet imo $SVRA Nov 22 PDUFA, 34 days out, and it is a Sunday so Friday is the real window. Molbreevi for autoimmune PAP, Priority Review with Breakthrough and Orphan in hand. the extension added time, not a warning, FDA cited no safety, efficacy or manufacturing concerns. closed 4.63 today, up 4 percent, right after JPMorgan showed up Oct 7 at Overweight with a 12 target. analysts rarely arrive early for no reason ngl

TRADE ALERT $SVRA setup is catalyst runup Entry zone: $4.60 to $4.85 Stop: $4.30 Targets: $5.10, then $5.60 Score: 71 Fourteen days to the Nov 22 PDUFA and Friday already showed the turn, up 10% off the 4.41 low and closing right near the high. Molbreevi is the first shot at aPAP with no approved therapy, IMPALA 2 met its endpoint and the data ran in NEJM. Binary risk is real, the filing was refused once before, so the stop is the whole point here.

$SVRA It's worth noting that institutional holdings have been increasing in past weeks from just under 85% about a month ago to well over 87% now.

$SVRA I believe that following the earnings announcement in November, the stock could surpass the $5–6 threshold; at that point, short covering might be triggered, which—combined with an FDA decision—could cause the stock to surge.

$SVRA I have a really hard time seeing a rejection by the FDA based on the two Impala trials, especially the solid long term data and affects on quality of life measures vs the WLL alternative.

$SVRA I have been here along time and based on their track record and history of the company, they have been unable to get this over the finish line, I think the market is now understanding they won't be able too. That is why so many shorts. Just tough to watch. A lot more people in the know than us. SVRA reputation for execution has been terrible, I am praying they get this done.

$SVRA sitting near strong support. Looking for a run back up to the resistance at around 6.60

Eighteen days out and $SVRA is still the quiet one on my board imo. Nov 22 PDUFA, a Sunday, so Friday is the practical window. Molbreevi for autoimmune PAP, Priority Review with Breakthrough and Orphan in hand, and IMPALA 2 already showed the gas transfer win that matters here. Trading near 4.59 today after JPMorgan showed up at Overweight with a 12 target. First therapy for a disease with no approved drug yet, that is the kind of setup I watch into the date, not away from it

$SVRA She always seems to go up when everything else is down. Hopefully she’s ready to jump another 7-20% tomorrow.

$SVRA my main question is whether an understaffed and chaotic mess of an FDA can get this done in the allotted time.

$SVRA Latest company news, Oct 21, 2026: Savara presented a post-hoc IMPALA analysis at CHEST 2026 in autoimmune PAP patients with mildly reduced or normal diffusing capacity (13 of 138 patients). On molgramostim the alveolar-arterial oxygen gradient fell 12.7 mmHg at Week 24, versus 0.3 mmHg on placebo. Exploratory, hypothesis-generating analysis. More details in our $SVRA stock hub. Not investment advice.

$SVRA interesting most of price targets were moved to 10+ over last year by the heavy hitters , whereas before they were topping out at 8 or so, just sayin'

$SVRA Guys, how do you think it’ll go? Getting failed because of the labeling seems absurd to me.

$SVRA Supporting SpaceMonkey1 posts: The core foundation of the BLA is the positive outcome of the Phase 3 IMPALA-2 clinical trial. * Key Metrics: The trial successfully met its endpoints, showing significant improvements in both exercise capacity and biomarker data for patients with autoimmune pulmonary alveolar proteinosis (aPAP). * Regulatory Weight: In rare diseases with clear-cut data and severe unmet needs, the FDA historically leans toward approval if the primary clinical endpoints are cleanly achieved.

$SVRA answered some A-a gradient questions. They looked at impala 1 patients with relatively preserved diffusion capacity but high A-a gradient, and found improvements over placebo, pretty large improvement, with molgramostim. Long term data on quality of life also looked good as did objective ground glass opacity. Sample size is small but good supporting data, nonetheless.

$SVRA I took a starter position this morning. Good action in after hours, will add more tomorrow if the trend continues.

📅 CATALYST REMINDER | $SVRA October 20–21, 2026 — Clinical Data Presentations Molgramostim long-term efficacy and safety analyses from IMPALA-2 will be presented at CHEST 2026; not a new pivotal readout. More details in our hub. #SVRA #Biotech #CHEST2026